NCT07863180 Tributyrin for Progressive Supranuclear Palsy (PSP): Virtual Trial
| NCT ID | NCT07863180 |
| Status | Recruiting |
| Phase | Phase 1, Phase 2 |
| Sponsor | Prabesh Kanel |
| Condition | Parkinson Disease |
| Study Type | INTERVENTIONAL |
| Enrollment | 15 participants |
| Start Date | 2026-10-01 |
| Primary Completion | 2027-05 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
Phase 1 is the earliest stage of human testing — safety and dosage are the primary focus. Visits are frequent and medical supervision is intensive. You will be among the first people to receive this treatment.
This trial targets 15 participants in total. It began in 2026-10-01 with a primary completion date of 2027-05.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This research is studying a supplement called tributyrin in people with Progressive Supranuclear Palsy (PSP) to learn about its safety and tolerability as a potential treatment. The goal of this research study is to see if a similar supplementation regimen and virtual testing is feasible for people with PSP.
Eligibility Criteria
Inclusion Criteria: * Male or Female, age 45 years and over. * Diagnosis of PSP-Richardson syndrome (RS) based on Movement Disorder Society (MDS) Criteria, including 1. Vertical supranuclear gaze palsy. 2. Repeated unprovoked falls OR tendency to fall on the pull test within 3 years. * Access to the internet and webcam for virtual visits. * Presence of a caregiver. Exclusion Criteria: * Recent history of significant, uncontrolled GI disease such as Gastroesophageal reflux disease, colorectal cancer. * Significant metabolic or uncontrolled medical comorbidity. * Regular use of typical anti-cholinergic drugs. * Women of child-bearing potential, or who are pregnant and/or nursing. * Suicidal ideation, as indicated by a response of 2 or 3 on question 9 of the Beck Depression Inventory. * Any other condition or criterion that, in the opinion of the investigators, would preclude safe and meaningful participation in the study.
Contact & Investigator
Prabesh Kanel, PhD
PRINCIPAL INVESTIGATOR
University of Michigan
Frequently Asked Questions
Who can join the NCT07863180 clinical trial?
This trial is open to participants of all sexes, aged 45 Years or older, studying Parkinson Disease. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
What phase is the NCT07863180 trial and what does that mean for participants?
Phase 1 trials are the first stage of human testing. The primary goal is to assess safety and determine appropriate dosage levels. Participants are closely monitored. These trials typically involve a small number of volunteers.
Is NCT07863180 currently recruiting?
Yes, NCT07863180 is actively recruiting participants. Contact the research team at natealex@med.umich.edu for enrollment information.
Where is the NCT07863180 trial being conducted?
This trial is being conducted at Ann Arbor, United States.
Who is sponsoring the NCT07863180 clinical trial?
NCT07863180 is sponsored by Prabesh Kanel. The principal investigator is Prabesh Kanel, PhD at University of Michigan. The trial plans to enroll 15 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.